Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04872790
Ignite Creation Date: 2024-05-06 @ 4:06 PM
Last Modification Date: 2024-10-26 @ 2:03 PM
Study NCT ID: NCT04872790
Protocol Section: NCT04872790
Start Identification Module Data
Expand Identification Module Data
Brief Title: Venetoclax Dasatinib Prednisone Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Official Title: A Dose-Finding Phase Ib Study of the Oral BCL-2 Inhibitor Venetoclax ABT-199 in Combination With Standard Induction Therapy Dasatinib Prednisone and Rituximab in CD20 Patients in Adult Patients With Newly Diagnosed and Relapsed Philadelphia Chromosome Positive ALL Ph ALL and Ph MPAL
Acronym: None
Organization: OHSU Knight Cancer Institute
Organization Class: OTHER
Organization Study ID: STUDY00022691
Secondary IDs
Secondary ID Type Domain Link
STUDY00022691 OTHER OHSU Knight Cancer Institute None
NCI-2021-01791 REGISTRY None None
Start Status Module Data
Status Verified Date: 2024-08
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: OHSU Knight Cancer Institute
Lead Sponsor Class: OTHER
Lead Sponsor: OHSU Knight Cancer Institute
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload